Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Duke University
Study ID
NCT00268359
Phase
PHASE2
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with irinotecan may kill more tumors cells. PURPOSE: This phase II trial is studying the side effects of bevacizumab and how well giving bevacizumab together with irinotecan works in treating patients with recurrent or refractory gliomas.

Key Dates

Start date
May 31, 2005
Status verified
Feb 2013
Primary completion
Aug 31, 2006
Completion
Oct 31, 2009

Study Design

Enrollment
68 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Safety

Locations (1)

FacilityCityStateZIPSite coordinators
Duke Comprehensive Cancer CenterDurhamNorth Carolina27710-

Find similar trials in Durham, NC

By research site
Duke Comprehensive Cancer Center· Durham, NC

Related Studies